De-risked, IP-protected, and advancing on the FDA 505(b)(2) pathway toward a strategic exit.
Androgenetic alopecia affects roughly half of men by age 50 and a large, underserved population of women. The prescription standards of care, minoxidil and finasteride, are decades old and single-mechanism. There is no FDA-approved topical prescription combination purpose-built around multiple established hair-growth mechanisms.
Patients and physicians often fall back on off-label or compounded mixes that lack FDA approval, market exclusivity, reimbursement, and IP protection.
Attain combines three established, well-characterized actives into a single patented topical prescription formulation, delivered topically to concentrate activity at the scalp and reduce the systemic exposure associated with oral treatment.
Type II 5-alpha-reductase inhibition.
Dual Type I and II 5-alpha-reductase inhibition.
Follicular stimulation and vasodilatory activity.
This is not a new-molecule discovery bet. The innovation is the protected combination, the topical formulation, the regulatory package, and the strategic positioning.
Attain is a capital-efficient, single-asset program. Rather than building a commercial company, we advance the asset to an FDA value inflection (Phase 1 or Phase 2) and position it for acquisition by a specialty or global pharmaceutical buyer with the infrastructure to commercialize it. Capital is deployed against defined FDA milestones.
Attain is raising a seed round on a SAFE to fund the program toward its FDA value inflection. Accredited investors can request the confidential overview and data room.
Request access